| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1137 | 2018 |
| Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of … S Hironaka, S Ueda, H Yasui, T Nishina, M Tsuda, T Tsumura, ... J clin oncol 31 (35), 4438-4444, 2013 | 557 | 2013 |
| Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer Y Yamada, K Higuchi, K Nishikawa, M Gotoh, N Fuse, N Sugimoto, ... Annals of Oncology 26 (1), 141-148, 2015 | 532 | 2015 |
| TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial T Yoshino, N Mizunuma, K Yamazaki, T Nishina, Y Komatsu, H Baba, ... The lancet oncology 13 (10), 993-1001, 2012 | 356 | 2012 |
| Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer T Doi, K Muro, N Boku, Y Yamada, T Nishina, H Takiuchi, Y Komatsu, ... J Clin Oncol 28 (11), 1904-1910, 2010 | 277 | 2010 |
| Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial S Siena, M Di Bartolomeo, K Raghav, T Masuishi, F Loupakis, ... The Lancet Oncology 22 (6), 779-789, 2021 | 273 | 2021 |
| Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies Y Nakamura, H Taniguchi, M Ikeda, H Bando, K Kato, C Morizane, T Esaki, ... Nature medicine 26 (12), 1859-1864, 2020 | 264 | 2020 |
| Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 … K Muro, N Boku, Y Shimada, A Tsuji, S Sameshima, H Baba, T Satoh, ... The lancet oncology 11 (9), 853-860, 2010 | 258 | 2010 |
| Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) K Yamazaki, M Nagase, H Tamagawa, S Ueda, T Tamura, K Murata, ... Annals of Oncology 27 (8), 1539-1546, 2016 | 252 | 2016 |
| Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system T Yamaguchi, N Machida, C Morizane, A Kasuga, H Takahashi, K Sudo, ... Cancer science 105 (9), 1176-1181, 2014 | 245 | 2014 |
| Routine endoscopy using a magnifying endoscope for gastric cancer diagnosis H Tajiri, T Doi, H Endo, T Nishina, T Terao, I Hyodo, K Matsuda, K Yagi Endoscopy 34 (10), 772-777, 2002 | 208 | 2002 |
| Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection J Nasu, T Doi, H Endo, T Nishina, S Hirasaki, I Hyodo Endoscopy 37 (10), 990-993, 2005 | 182 | 2005 |
| Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial K Shitara, A Takashima, K Fujitani, K Koeda, H Hara, N Nakayama, ... The lancet Gastroenterology & hepatology 2 (4), 277-287, 2017 | 177 | 2017 |
| Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced … J Matsubara, T Nishina, Y Yamada, T Moriwaki, T Shimoda, T Kajiwara, ... British Journal of Cancer 98 (4), 832-839, 2008 | 139 | 2008 |
| Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial Y Nakamura, W Okamoto, T Kato, T Esaki, K Kato, Y Komatsu, S Yuki, ... Nature medicine 27 (11), 1899-1903, 2021 | 137 | 2021 |
| TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm … Y Kuboki, T Nishina, E Shinozaki, K Yamazaki, K Shitara, W Okamoto, ... The Lancet Oncology 18 (9), 1172-1181, 2017 | 137 | 2017 |
| A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer N Saeki, A Saito, IJ Choi, K Matsuo, S Ohnami, H Totsuka, S Chiku, ... Gastroenterology 140 (3), 892-902, 2011 | 136 | 2011 |
| Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients N Fuse, Y Kuboki, T Kuwata, T Nishina, S Kadowaki, E Shinozaki, ... Gastric cancer 19, 183-191, 2016 | 131 | 2016 |
| Perceptions and attitudes of clinical oncologists on complementary and alternative medicine: A nationwide survey in Japan I Hyodo, K Eguchi, T Nishina, H Endo, M Tanimizu, I Mikami, S Takashima, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 125 | 2003 |
| Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer … A Sawaki, Y Ohashi, Y Omuro, T Satoh, Y Hamamoto, N Boku, Y Miyata, ... Gastric Cancer 15, 313-322, 2012 | 124 | 2012 |
